Analysts See $-0.41 EPS for Cytokinetics, (CYTK); Northrim Bancorp (NRIM) SI Decreased By 23.03%

April 12, 2018 - By Winifred Garcia

Cytokinetics, Incorporated (NASDAQ:CYTK) Logo

Analysts expect Cytokinetics, Incorporated (NASDAQ:CYTK) to report $-0.41 EPS on April, 26.They anticipate $0.21 EPS change or 33.87% from last quarter’s $-0.62 EPS. After having $-0.75 EPS previously, Cytokinetics, Incorporated’s analysts see -45.33% EPS growth. The stock increased 1.37% or $0.1 during the last trading session, reaching $7.4. About 135,410 shares traded. Cytokinetics, Incorporated (NASDAQ:CYTK) has declined 40.55% since April 12, 2017 and is downtrending. It has underperformed by 52.10% the S&P500.

Northrim Bancorp Inc (NASDAQ:NRIM) had a decrease of 23.03% in short interest. NRIM’s SI was 57,500 shares in April as released by FINRA. Its down 23.03% from 74,700 shares previously. With 11,300 avg volume, 5 days are for Northrim Bancorp Inc (NASDAQ:NRIM)’s short sellers to cover NRIM’s short positions. The SI to Northrim Bancorp Inc’s float is 0.86%. The stock increased 2.43% or $0.85 during the last trading session, reaching $35.85. About 18,417 shares traded or 35.92% up from the average. Northrim BanCorp, Inc. (NASDAQ:NRIM) has risen 16.67% since April 12, 2017 and is uptrending. It has outperformed by 5.12% the S&P500.

Among 12 analysts covering Cytokinetics (NASDAQ:CYTK), 11 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Cytokinetics had 23 analyst reports since July 24, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, October 10 by Piper Jaffray. The firm earned “Overweight” rating on Friday, October 6 by Morgan Stanley. The rating was maintained by FBR Capital with “Outperform” on Tuesday, November 10. Cantor Fitzgerald downgraded the stock to “Neutral” rating in Wednesday, November 22 report. The rating was upgraded by Needham to “Strong Buy” on Monday, February 6. The company was maintained on Monday, November 9 by Roth Capital. The stock of Cytokinetics, Incorporated (NASDAQ:CYTK) earned “Overweight” rating by Morgan Stanley on Wednesday, February 21. On Tuesday, November 21 the stock rating was maintained by Piper Jaffray with “Buy”. The stock of Cytokinetics, Incorporated (NASDAQ:CYTK) has “Buy” rating given on Wednesday, November 22 by Morgan Stanley. JMP Securities maintained Cytokinetics, Incorporated (NASDAQ:CYTK) on Wednesday, March 9 with “Market Outperform” rating.

Investors sentiment decreased to 1.11 in 2017 Q4. Its down 0.28, from 1.39 in 2017Q3. It is negative, as 15 investors sold Cytokinetics, Incorporated shares while 39 reduced holdings. 24 funds opened positions while 36 raised stakes. 38.16 million shares or 2.44% less from 39.12 million shares in 2017Q3 were reported. Citigroup invested in 0.01% or 819,028 shares. Quantbot Tech Ltd Partnership invested in 2,577 shares. Employees Retirement Systems Of Ohio invested 0% of its portfolio in Cytokinetics, Incorporated (NASDAQ:CYTK). Price T Rowe Associates Md has invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Moreover, Hall Laurie J Trustee has 0% invested in Cytokinetics, Incorporated (NASDAQ:CYTK). New York-based Metropolitan Life Ins New York has invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). 40,000 were reported by Weiss Multi. State Of Tennessee Treasury Department stated it has 0% of its portfolio in Cytokinetics, Incorporated (NASDAQ:CYTK). Td Asset Mgmt Incorporated, Ontario – Canada-based fund reported 18,300 shares. Palo Alto Limited Com holds 0.04% or 123,686 shares in its portfolio. Barclays Public Ltd Company accumulated 19,297 shares or 0% of the stock. Macquarie Gru has 0% invested in Cytokinetics, Incorporated (NASDAQ:CYTK). Cornerstone Mngmt Holdg Ltd Liability Co holds 15,411 shares. Wells Fargo Mn invested in 0% or 72,247 shares. Virtu Financial Lc holds 13,720 shares or 0.01% of its portfolio.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company has market cap of $399.66 million. The firm is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. It currently has negative earnings. The Company’s lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis.

Since January 16, 2018, it had 0 insider buys, and 2 selling transactions for $54,471 activity. McDowell Caryn Gordon sold $24,381 worth of stock. 4,000 shares were sold by Blum Robert I, worth $30,090 on Thursday, April 5.

Northrim BanCorp, Inc. operates as bank holding firm for Northrim Bank that provides commercial banking services and products to businesses and professional individuals primarily in Alaska. The company has market cap of $246.36 million. The firm operates in two divisions, Community Banking and Home Mortgage Lending. It has a 19.07 P/E ratio. It offers various deposit products, including noninterest-bearing checking accounts and interest-bearing time deposits, checking accounts, and savings accounts, as well as money market deposit accounts, certificates of deposit, and courier noncash deposits.

Investors sentiment decreased to 1.19 in 2017 Q4. Its down 0.59, from 1.78 in 2017Q3. It turned negative, as 4 investors sold Northrim BanCorp, Inc. shares while 28 reduced holdings. 15 funds opened positions while 23 raised stakes. 4.77 million shares or 1.99% less from 4.87 million shares in 2017Q3 were reported. Millennium Mgmt Ltd invested 0% in Northrim BanCorp, Inc. (NASDAQ:NRIM). Deutsche State Bank Ag owns 36,520 shares for 0% of their portfolio. Vanguard Gp holds 0% in Northrim BanCorp, Inc. (NASDAQ:NRIM) or 292,933 shares. Fifth Third Savings Bank has 0% invested in Northrim BanCorp, Inc. (NASDAQ:NRIM). Manufacturers Life Company The reported 224,120 shares. Foundry Prtnrs Ltd Liability, a Minnesota-based fund reported 59,415 shares. The New York-based First Manhattan has invested 0% in Northrim BanCorp, Inc. (NASDAQ:NRIM). Barclays Public Ltd Com holds 0% or 1,075 shares in its portfolio. Bancorporation Of America De has 0% invested in Northrim BanCorp, Inc. (NASDAQ:NRIM) for 6,036 shares. Citigroup Incorporated invested in 0% or 4,338 shares. Moreover, Pacific Ridge Capital Prtn Ltd Com has 0.68% invested in Northrim BanCorp, Inc. (NASDAQ:NRIM). Parallax Volatility Advisers L P invested 0% of its portfolio in Northrim BanCorp, Inc. (NASDAQ:NRIM). The Ohio-based Meeder Asset Mgmt Inc has invested 0% in Northrim BanCorp, Inc. (NASDAQ:NRIM). Seizert Prtn Ltd Com invested in 0.11% or 92,437 shares. 43,604 are held by Brandes Ptnrs Lp.

Cytokinetics, Incorporated (NASDAQ:CYTK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Winifred Garcia

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: